Ország: Kanada
Nyelv: angol
Forrás: Health Canada
FLUCONAZOLE
APOTEX INC
J02AC01
FLUCONAZOLE
200MG
TABLET
FLUCONAZOLE 200MG
ORAL
100
Prescription
AZOLES
Active ingredient group (AIG) number: 0122529006; AHFS:
APPROVED
1998-10-09
_APO-FLUCONAZOLE (Fluconazole Tablets) _ _ _ _Page 1 of 58 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr APO-FLUCONAZOLE Fluconazole Tablets Tablets, 50 mg, 100 mg and 200 mg, oral Apotex Standard Antifungal Agent APOTEX INC. 150 Signet Drive Toronto, Ontario M9L 1T9 Date of Initial Authorization: OCT 09, 1998 Date of Revision: NOV 16, 2022 Submission Control Number: 264805 _APO-FLUCONAZOLE (Fluconazole Tablets) _ _ _ _Page 2 of 58 _ RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS 11/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES............................................................................................. 2 TABLE OF CONTENTS............................................................................................................... 2 1 INDICATIONS.................................................................................................................... 4 1.1 Pediatrics (<18 years of age) ....................................................................................... 4 1.2 Geriatrics ................................................................................................................... 4 2 CONTRAINDICATIONS ...................................................................................................... 5 4 DOSAGE AND ADMINISTRATION ...................................................................................... 5 4.1 Dosing Considerations ................................................................................................ 5 4.2 Recommended Dose and Dosage Adjustment ............................................................. 5 4.5 Missed Dose............................................................................................................... 8 5 OVERDOSAGE................................................................................................................... 8 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND P Olvassa el a teljes dokumentumot